Țară: Australia
Limbă: engleză
Sursă: Department of Health (Therapeutic Goods Administration)
testosterone, Quantity: 10 mg/mL
Lawley Pharmaceuticals Pty Ltd
Cream
Excipient Ingredients: Almond oil; butylated hydroxytoluene; carbomer 940; cetomacrogol 1000; cetostearyl alcohol; citric acid; dl-alpha-tocopheryl acetate; trolamine; purified water; phenoxyethanol; propyl hydroxybenzoate; ethyl hydroxybenzoate; isobutyl hydroxybenzoate; butyl hydroxybenzoate; methyl hydroxybenzoate
Topical
50 mL
(S4) Prescription Only Medicine
ANDROFEME 1 is indicated for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women. Therapeutic intervention with ANDROFEME 1 should only be initiated in women following failure of appropriate education and correction of modifiable biopsychosocial factors (which may include neuroendocrine imbalance, physical ill health or disease, interpersonal difficulties, psychological distress or specific cultural or religious beliefs), according to the International Society for the Study of Women?s Sexual Health (ISSWSH) process of care (see Figure 1).
Visual Identification: White soft cream with faint odour of emulsifying wax with a fine dispersion of testosterone particles; Container Type: Tube; Container Material: Other plastic laminate/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2020-11-23
ANDROFEME ® 1 - January 2021 1 ANDROFEME® 1 CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING ANDROFEME 1? ANDROFEME 1 contains the active ingredient testosterone. ANDROFEME 1 is used to treat postmenopausal women with hypoactive sexual desire dysfunction. For more information, see Section 1. Why am I using ANDROFEME 1? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE ANDROFEME 1? Do not use if you have ever had an allergic reaction to testosterone, tree nuts (almond oil) or any of the ingredients listed at the end of the CMI. Do not use if you have or have had any of the following: • breast cancer or any other cancer which your doctor has described as being caused or stimulated by androgen • kidney disease known as nephrotic syndrome • blockage of a blood vessel by a blood clot (thromboembolism) • high calcium levels in the blood (hypercalcaemia) Do not use if you: still menstruate; are pregnant or breastfeeding; are a child. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use ANDROFEME 1? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with ANDROFEME 1 and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE ANDROFEME 1? • The usual starting dose is 0.5 mL (5 mg) of cream by measured applicator per day. • Detailed instructions on how to safely use the applicator syringe and cream can be found in Section 4. How do I use ANDROFEME 1? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING ANDROFEME 1? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using ANDROFEME 1. Keep all appointments to monitor your progress. • Contact your doctor Citiți documentul complet
AndroFeme1-pi-aust--November-2020 Page 1 of 16 AUSTRALIAN PRODUCT INFORMATION – ANDROFEME ® 1 (TESTOSTERONE) 1% W/V CREAM 1 NAME OF THE MEDICINE Testosterone 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ANDROFEME 1 contains 1% w/v testosterone (10 mg testosterone per 1 mL). Contains tree nut products (almond oil) and hydroxybenzoates. For the full list of excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Cream. ANDROFEME 1 is a white, opaque, oil-in-water cream. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ANDROFEME 1 is indicated for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women. Therapeutic intervention with ANDROFEME 1 should only be initiated in women following failure of appropriate education and correction of modifiable biopsychosocial factors (which may include neuroendocrine imbalance, physical ill health or disease, interpersonal difficulties, psychological distress or specific cultural or religious beliefs), according to the International Society for the Study of Women’s Sexual Health (ISSWSH) process of care (see Figure 1). AndroFeme1-pi-aust--November-2020 Page 2 of 16 4.2 DOSE AND METHOD OF ADMINISTRATION DOSE The recommended starting dose is 5 mg testosterone (0.5 mL) applied once daily, at approximately the same time each day, to either the upper outer thigh or buttock. If no improvement in symptoms is seen within 3 months and if the testosterone concentration is within the premenopausal reference range a dose increase up to 10 mg testosterone (1.0 mL) daily can be used with follow up clinical and biochemical monitoring. This dose should only rarely be exceeded. (See Monitoring) Clinical trials have shown that there is a four to eight-week time lag between starting testosterone treatment and an improvement in sexual motivation. If there is no improvement in symptoms after 6 months of continuous therapy, treatment should be discontinued and alternative options be considered. METHOD OF ADMINISTRATION The patient should be directed to Citiți documentul complet